The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Michael Schieber, Shuo Ma Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA Abstract: The BCL-2 protein family members inhibit cellular apoptosis, and their overexpression repre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Schieber M, Ma S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	CLL SLL venetoclax BCL2 Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/bda0a302eee5436c9798e812c776575e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bda0a302eee5436c9798e812c776575e
record_format	dspace
spelling	oai:doaj.org-article:bda0a302eee5436c9798e812c776575e2021-12-02T06:21:48ZThe expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma1179-9889https://doaj.org/article/bda0a302eee5436c9798e812c776575e2019-03-01T00:00:00Zhttps://www.dovepress.com/the-expanding-role-of-venetoclax-in-chronic-lymphocytic-leukemia-and-s-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Michael Schieber, Shuo Ma Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA Abstract: The BCL-2 protein family members inhibit cellular apoptosis, and their overexpression represents a common survival adaption in cancer. Recently, a selective BCL-2 inhibitor ABT-199, venetoclax, has demonstrated remarkable activity in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), both as a single agent and in combination with anti-CD20 immunotherapies, such as rituximab. In this article, we review the development and latest clinical data that have led to the expanded approval of venetoclax with rituximab in relapsed/refractory CLL/SLL. We also discuss ongoing and future clinical trials designed to evaluate the efficacy of venetoclax in previously untreated patients and to investigate venetoclax combinations with inhibitors of B-cell receptor signaling pathway. These studies hope to offer an expanded list of chemotherapy-free regimens for patients with CLL/SLL. Keywords: CLL, SLL, venetoclax, BCL2Schieber MMa SDove Medical PressarticleCLLSLLvenetoclaxBCL2Diseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol Volume 9, Pp 9-17 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	CLL SLL venetoclax BCL2 Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	CLL SLL venetoclax BCL2 Diseases of the blood and blood-forming organs RC633-647.5 Schieber M Ma S The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
description	Michael Schieber, Shuo Ma Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA Abstract: The BCL-2 protein family members inhibit cellular apoptosis, and their overexpression represents a common survival adaption in cancer. Recently, a selective BCL-2 inhibitor ABT-199, venetoclax, has demonstrated remarkable activity in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), both as a single agent and in combination with anti-CD20 immunotherapies, such as rituximab. In this article, we review the development and latest clinical data that have led to the expanded approval of venetoclax with rituximab in relapsed/refractory CLL/SLL. We also discuss ongoing and future clinical trials designed to evaluate the efficacy of venetoclax in previously untreated patients and to investigate venetoclax combinations with inhibitors of B-cell receptor signaling pathway. These studies hope to offer an expanded list of chemotherapy-free regimens for patients with CLL/SLL. Keywords: CLL, SLL, venetoclax, BCL2
format	article
author	Schieber M Ma S
author_facet	Schieber M Ma S
author_sort	Schieber M
title	The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
title_short	The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
title_full	The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
title_fullStr	The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
title_full_unstemmed	The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
title_sort	expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/bda0a302eee5436c9798e812c776575e
work_keys_str_mv	AT schieberm theexpandingroleofvenetoclaxinchroniclymphocyticleukemiaandsmalllymphocyticlymphoma AT mas theexpandingroleofvenetoclaxinchroniclymphocyticleukemiaandsmalllymphocyticlymphoma AT schieberm expandingroleofvenetoclaxinchroniclymphocyticleukemiaandsmalllymphocyticlymphoma AT mas expandingroleofvenetoclaxinchroniclymphocyticleukemiaandsmalllymphocyticlymphoma
_version_	1718399960591892480

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma

Ejemplares similares